NS3-CMPK-hLBR1TM-mEGFP

300986

GENERAL INFORMATION

Description

□□□□□□□□□□□□□□□□□□□□ Flp □□□□□□□□□□□□□□□□□□

Tissue	□□□□□
Disease	□□
Metastatic site	□□□□□□□□□□□□□□□□□□

Applications

□□□□□□□□ B □□□LBR□□□□□□□□□□□□□□□□□□HeLa Kyoto FlpIn TREx □□□□□□□□□□□□□□□□□□□□□□□□ NS3 □□□□□□□□□□ □□□□□□□

Synonyms

- HeLa R19 FlpIn TREx H2B-Cherry/NS3-CMPK-hLBR1TM-mEGFP

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This HeLa R19 FlpIn TREx derivative contains Flp recombinase-integrated constructs encoding H2B-mCherry and doxycycline-inducible NS3-CMPK-hLBR1TM-mEGFP, with G418 resistance marker. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Morphology	□□□
Cell type	□□□□

IDENTIFIERS

Citation

NS3-CMPK-hLBR1TM-mEGFP□Cytion □□ 300986□

NCBI TaxID	9606
Cellosaurus	CVCL_UR51

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

EXPRESSION AND SUSCEPTIBILITY

Protein expression

H2B-mCherry □ DOx □□□ NS3-CMPK-hLBR1TM-mEGFP

HANDLING AND CULTURE

Culture medium

DMEM□□ 4.5 g/L □□□□4 mM L-□□□□□3.7 g/L $NaHCO_3$ □ 1.0 mM □□□□□Cytion □□□□ 820300a□

Incubation atmosphere	37°C□5% CO_2□□□□□□

Supplements

□□□□□□□ 10% FBS □ 0.5 mg/mL G418

Dissociation reagent	Accutase

Subculturing

□□□□□□□□□□□□□□□□□□□□□□□□PBS□□□□□T25□□□□□3-5□□PBS□T75□□□□□□5-10□□□ □□□□ Accutase □□□□□□□T25 □□□□□ 1–2 □□□T75 □□□□□□ 2.5 □□□□□□□□□□□□ 8–10 □□□□□□□□ □□□□□□□□ 10 □□□□□□□□□□□□□□□□□□□□ 300xg □□ 3 □□□□ □□□□□□□□□□□□□□□□□□□□

Ethnicity	□□□□□

LEGAL AND SAFETY

Safety precautions

□□□□